Episurf Medical - Q1’22 Review
2022-05-02 10:00:00
Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and notes several crucial activities carried out that should ignite a more significant sales growth beyond 2022.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/